- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00106431
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Responses were evaluated according to a composite assessment (Objective Primary Disease Response Evaluation Criteria [OPDREC]) that included cutaneous manifestations of disease, lymph node involvement, and circulating malignant T-cells (Sézary cells). Skin involvement was measured using a weighted body surface area skin assessment tool (WBSA/SWAT) or an erythroderma score, depending upon the pt's disease. Disease response was assessed by the Investigators and an Independent Response Review Committee (IRRC) with the IRRC assessment considered supportive of the Investigator's evaluations using the following criteria:
Complete Response (CR):
- Complete resolution of skin patches, skin plaques, and skin tumors, or erythroderma
- No evidence of abnormal lymph nodes
- Absence of circulating Sézary cells.
- No evidence of new tumors (cutaneous or non-cutaneous)
- Findings confirmed by skin biopsy
Clinical complete response (CCR):
- Same as CR but without skin biopsy
Partial Response (PR):
- ≥50% improvement in the summation of (change in Skin + change in Lymph Node + change in Peripheral Blood) with
- At least >30% improvement in Skin and
- No worsening in Lymph Node or Sézary cells.
- No evidence of new tumors (cutaneous/non-cutaneous)
Stable Disease (SD):
- Not enough improvement or worsening in the summation of (change in Skin + change in Lymph Node + change in Peripheral Blood to qualify as PR or PD
- No evidence of new tumors (cutaneous/non-cutaneous)
SD90:
- SD90 was defined as documented evidence of SD for at least 90 Days Duration
Progressive Disease (PD):
- Evidence of new tumor (cutaneous or non-cutaneous), OR
- >25% worsening in the summation of (change in Skin + change in Lymph Node + change in Peripheral Blood) with >15% worsening in change in Skin.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Multiple Locations, France
- Research Site
-
-
-
-
-
Multiple Locations, Germany
- Research Site
-
-
-
-
-
Multiple Locations, Poland
- Research Site
-
-
-
-
-
Multiple Locations, Russian Federation
- Research Site
-
-
-
-
-
Multiple Locations, United Kingdom
- Research Site
-
-
-
-
California
-
Los Angeles, California, United States, 90095
- UCLA Jonsson Cancer Center
-
Stanford, California, United States, 94305
- Stanford Comprehensive Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Abrahamson Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt-Ingram Cancer Center
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Patients had to fulfill all of the following criteria to be eligible for study participation:
- Males or non-pregnant females aged 18 or over.
- Histologically confirmed diagnosis of CTCL, including mycosis fungoides and Sézary syndrome.
- Patients with CTCL stages II-A, II-B, III, and IV-A only.
- Patients with CTCL stage IB who had relapsed following previous therapy and where, in the investigator's opinion, the potential benefit of treatment with romidepsin outweighed the possible risks.
- Patients who had failed standardized skin-directed therapy and had had at least one course of systemic therapy, such as interferon, Ontak®, chemotherapy or Targretin®, etc., which they were deemed to have failed.
- Anticipated life expectancy greater than six months.
- Written informed consent to participate in the study.
Exclusion Criteria: Patients were ineligible for entry if any of the following criteria were met:
- ECOG Performance Status >1.
- Patients who had not received at least 1 course of prior systemic therapy for CTCL.
- Visceral involvement i.e. Stage 4B disease (lymphadenopathy was allowed).
Patients with known cardiac abnormalities such as:
- Congenital long QT syndrome
- QTc (Corrected QT interval on ECG) interval >480 milliseconds
- Any cardiac arrhythmia requiring anti-arrhythmic medication.
- Patients who had had a myocardial infarction within 12 months of study entry.
- Patients who had a history of coronary artery disease (CAD) e.g. angina Canadian class II to IV. In any patient in whom there was doubt, the patient should have had a stress imaging study and exercise electrocardiogram (ECG) and, if abnormal, angiography to define whether or not CAD was present.
- Patients with an ECG recorded at screening showing evidence of cardiac ischaemia (ST depression of >=2 mm). If in any doubt, the patient should have had a stress imaging study and exercise ECG and, if abnormal, angiography to define whether or not CAD is present.
- Patients with congestive heart failure that met New York Heart Association class II to IV definitions and/or ejection fraction <40% by multiple gated acquisition (MUGA) scan or <50% by echocardiogram and/or magnetic resonance imaging (MRI)
- Patients with a history of sustained ventricular tachycardia (VT), ventricular fibrillation (VF), Torsade de Pointes, or cardiac arrest, unless currently addressed with an automatic implantable cardioverter defibrillator (AICD).
- Patients with hypertrophic cardiomegaly or restrictive cardiomyopathy from prior treatment or other causes (if in doubt, see ejection fraction criteria above).
- Patients with uncontrolled hypertension, i.e. >=160/95 mmHg.
- Concomitant use of any anti-cancer therapy.
- Concomitant use of warfarin (due to a drug interaction).
- Concomitant use of any investigational agent.
- Use of any investigational agent within 4 weeks of study entry.
- Concomitant use of drugs which may cause a prolongation of the QTc interval.
- Patients with a potassium level of <3.5 mmol/L and a magnesium level of <0.8 mmol/L.
- Clinically significant active infection.
- Known infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
Inadequate bone marrow or other organ function, as evidenced by:
- unsupported haemoglobin <9.0 g/dL (transfusions and/or erythropoietin were permitted);
- absolute neutrophil count (ANC) <=1.5 x 10^9/L;
- platelet count <100 x 10^9/L;
- total bilirubin >1.25 x upper limit of normal (ULN) for institution,
- aspartate transaminase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine transaminase/ glutamic pyruvic transaminase (ALT/SGPT) >2.0 x ULN, serum creatinine >2.0 x ULN for age and sex;
- Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin or cervical epithelial neoplasm [CIN1, carcinoma in situ] that had been treated curatively).
- Any significant medical or psychiatric condition that might have prevented the patient from complying with all study procedures.
- Patients who were pregnant or breast-feeding. All women of child bearing potential were to use an effective method of contraception (either an intrauterine device or a double barrier method using condoms or a diaphragm plus spermicide) during the study and for at least one month after receiving the last dose of romidepsin. Male patients were to use a barrier method of contraception (condoms) during the treatment period and for at least 1 month thereafter. Hormonal methods of contraception such as the contraceptive pill or patch (particularly those containing ethinyl estradiol) were to be avoided due to a potential drug interaction.
- Use of topical steroids in the previous 2 weeks or systemic steroids in the previous 4 weeks.
- Having previously given consent to participate in this study.
- Concomitant use of CYP3A4 inhibitors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Percent of Patients (Pts) With Objective Disease Response
Time Frame: 6 months
|
The percent of pts with confirmed Objective Disease Response (confirmed best responses of complete response [CR], clinical complete response [CCR], or partial response [PR]).
Responses were evaluated according to a composite assessment (Objective Primary Disease Response Evaluation Criteria - OPDREC).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Objective Disease Response
Time Frame: Up to 10 months; median duration of follow up was 5.1 months
|
Duration of Objective Response was defined as the number of months from the date of the first disease response (clinical complete response [CCR], or partial response [PR]) (later confirmed) until the date of progression and was determined using Kaplan-Meier product-limit estimates.
In this analysis, pts who did not progress were censored as of their last evaluation with an OPDREC assessment.
|
Up to 10 months; median duration of follow up was 5.1 months
|
Time to Objective Disease Response
Time Frame: Up to 10 months
|
Time to Objective Response was defined as the time in months from first dose date to the first date of objective disease response (later confirmed) and time to CCR was defined as the time in months from first dose date to the first date of CCR (later confirmed).
|
Up to 10 months
|
Time to Disease Progression
Time Frame: Up to 10 months; median duration of follow up was 6.1 months
|
Time To Progression was defined as the duration from the date of the first study drug dose to the date of progression (PD).
In this analysis, pts who did not progress were censored at their last evaluation with an OPDREC assessment.
|
Up to 10 months; median duration of follow up was 6.1 months
|
Decrease in Pruritus Visual Analogue Scale (VAS) Score of ≥30 mm or a Score of 0 for at Least 2 Consecutive Cycles.
Time Frame: Up to 10 months
|
Pruritus was reported monthly by pts using a 0 (no itching) to 100 (unbearable itching) mm visual analog scale (VAS).
Pts were considered to have significant pruritus if the baseline VAS score was ≥ 30 mm.
Clinically meaningful reduction in pruritus was defined as a decrease in VAS score of ≥ 30 mm or a score of 0 for at least 2 consecutive cycles.
|
Up to 10 months
|
Duration of Objective Disease Control (ODC)
Time Frame: Up to 10 months; median duration of follow up was 6.0 months
|
For pts with confirmed ODC (pts with CR, CCR, PR, SD90 [stable disease for 90 days]) based on OPDREC, duration of ODC was summarized with descriptive statistics, including number of censored observations, and 25th, 50th, 75th percentiles of distribution, based on Kaplan-Meier product limit estimates.
For pts with confirmed progressive disease (PD), duration of ODC was calculated from first date of study drug to first date of diagnosis of confirmed PD.
For pts without confirmed PD, duration of ODC was calculated from first date of study drug to date of the last visit with any OPDREC data.
|
Up to 10 months; median duration of follow up was 6.0 months
|
Percent of Pts With Objective Disease Control
Time Frame: Up to 10 months
|
The percent of pts with confirmed ODC (CR, CCR, PR and SD90) based on OPDREC was summarized.
|
Up to 10 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Jean Nichols, Ph.D., Gloucester Pharmaceuticals, Inc.
Publications and helpful links
General Publications
- Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018 Apr;59(4):880-887. doi: 10.1080/10428194.2017.1361022. Epub 2017 Aug 30.
- Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov;16(11):637-643. doi: 10.1016/j.clml.2016.08.009. Epub 2016 Aug 10.
- Foss F, Coiffier B, Horwitz S, Pro B, Prince HM, Sokol L, Greenwood M, Lerner A, Caballero D, Baran E, Kim E, Nichols J, Balser B, Wolfson J, Whittaker S. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomark Res. 2014 Sep 8;2:16. doi: 10.1186/2050-7771-2-16. eCollection 2014.
- Demierre M, et al. Pooled analyses of two international, multicenter clinical studies of romidepsin in 167 patients with cutaneous T-cell lymphoma (CTCL). Presented at 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orlando, FL. Abstract No: 8546. J Clin Oncol 27:15s, 2009 (suppl)
- Cabell C, et al. Systematic Assessment of Potential Cardiac Effects of the Novel Histone Deacetylase (HDAC) Inhibitor Romidepsin. Presented at 2009 ASCO Annual Meeting, May 29-June 2, 2009, Orlando, FL. Abstract No: e19533. C J Clin Oncol 2009;27(suppl)
- Kim YH, et al. Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement. Presented at American Society of Hematology 2009, New Orleans, LA. Abstract No. 2683.
- Whittaker SJ, Demierre MF, Kim EJ, Rook AH, Lerner A, Duvic M, Scarisbrick J, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Kim YH. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010 Oct 10;28(29):4485-91. doi: 10.1200/JCO.2010.28.9066. Epub 2010 Aug 9.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell, Cutaneous
- Antineoplastic Agents
- Antibiotics, Antineoplastic
- Romidepsin
Other Study ID Numbers
- GPI-04-0001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous T-cell Lymphoma
-
University of WashingtonNational Cancer Institute (NCI)TerminatedCutaneous T-cell Lymphoma Stage I | Cutaneous T-cell Lymphoma Stage II | Cutaneous T-cell Lymphoma Stage III | Cutaneous T-cell Lymphoma Stage IVUnited States
-
SciTech Development, LLCRush University Medical CenterRecruitingMycosis Fungoides | Cutaneous T-cell Lymphoma | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Cutaneous/Peripheral T-Cell Lymphoma | Peripheral T-Cell Lymphoma, Not Classified | Primary Cutaneous T-cell Lymphoma | Cutaneous T-Cell Lymphoma, Unspecified | Follicular... and other conditionsUnited States
-
Kyowa Kirin, Inc.Active, not recruitingCutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma, RelapsedUnited States, United Kingdom, Spain, France, Italy
-
John ReneauActive, not recruitingRecurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma | Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin... and other conditionsUnited States
-
Weiyun AiCelgene CorporationCompletedLymphoma | T-Cell Lymphoma | Cutaneous LymphomaUnited States
-
Dana-Farber Cancer InstituteRecruitingCutaneous T Cell Lymphoma | Peripheral T Cell LymphomaUnited States
-
Legend Biotech USA IncActive, not recruitingT-Cell Lymphoma | Peripheral T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Refractory | Cutaneous T-Cell Lymphoma Recurrent | Peripheral T-Cell Lymphoma RecurrentUnited States
-
Northwestern UniversityNot yet recruitingCutaneous T Cell LymphomaUnited States
-
Universitätsmedizin MannheimKlinikum Ludwigshafen; Wuerzburg University Hospital; KKS Netzwerk; Klinikum Minden and other collaboratorsCompletedCutaneous T Cell LymphomaGermany
-
Codiak BioSciencesTerminatedCutaneous T-cell Lymphoma (CTCL)United Kingdom
Clinical Trials on romidepsin (depsipeptide, FK228)
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Giant Cell Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
National Cancer Institute (NCI)Completed
-
CelgeneCompletedPeripheral T-cell LymphomaUnited States, Spain, Germany, France, Czechia, Australia, Sweden, United Kingdom, Ukraine, Poland
-
Southwest Oncology GroupNational Cancer Institute (NCI)TerminatedBladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer
-
CelgeneTerminated
-
CelgeneCompletedCarcinoma, Renal Cell | Prostatic NeoplasmsUnited States, United Kingdom
-
CelgeneCompletedCarcinoma, Renal Cell | Neoplasm MetastasisUnited States
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)TerminatedMelanoma | Malignant Melanoma
-
National Cancer Institute (NCI)CompletedGastrointestinal Stromal Tumor | Recurrent Adult Soft Tissue Sarcoma | Stage III Adult Soft Tissue Sarcoma | Stage IV Adult Soft Tissue Sarcoma | Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Adult Rhabdomyosarcoma | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal... and other conditions
-
University of ChicagoNational Cancer Institute (NCI)WithdrawnOvarian CancerUnited States